eFFECTOR Therapeutics (EFTRW) Stock Price, News & Analysis

Company Overview

eFFECTOR Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapeutics that modulate protein synthesis to treat cancer and other serious diseases. The company’s proprietary platform targets key regulators of the translation machinery, aiming to selectively disrupt aberrant protein production that drives tumor growth and progression. By leveraging a deep understanding of translation biology, eFFECTOR seeks to develop precision medicines with differentiated mechanisms of action.

The company’s lead program, eFT226 (zotatifin), is a first‐in‐class inhibitor of the eukaryotic initiation factor 4A (eIF4A) that is being evaluated in Phase 1/2 clinical trials for a range of solid tumors and hematologic malignancies. In addition to zotatifin, eFFECTOR maintains a pipeline of preclinical candidates designed to address other facets of translational regulation, with the goal of expanding into rare diseases and additional oncology indications.

Founded in 2013 and headquartered in San Diego, California, eFFECTOR Therapeutics collaborates with academic institutions and research centers around the world to accelerate its programs through partnerships and strategic alliances. The leadership team combines expertise in oncology, drug discovery, and clinical development, guiding the company’s efforts to translate novel biology into therapeutic advances.

Through its targeted approach to protein translation, eFFECTOR aims to bring new treatment options to patients with high unmet needs. By combining a robust discovery engine with clinical development capabilities, the company is positioned to explore the full therapeutic potential of translation modulators across multiple disease areas.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 38,718 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EFTRW Stock Analysis - Frequently Asked Questions

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EFTRW
• CIK: 1828522
• Web: effector.com
• Phone: 18589258215
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A